Jerry Chapman

Senior GMP Quality Expert

Areas examined in this report:

  • Pharma compliance issue trends
  • The role of EIRs
  • When FDA inspections are classified as OAI
  • Timing of surveillance inspections following pre-approval inspections
  • A case study in contamination failures that led to patient deaths
  • The series of events that resulted in a company coming under a consent decree